Apyx Medical (APYX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	28.01 mm	28.01 mm	28.01 mm	28.01 mm	28.01 mm	28.01 mm
Cash burn (monthly)	1.56 mm	(no burn)	1.55 mm	2.36 mm	1.48 mm	1.44 mm
Cash used (since last report)	7.90 mm	n/a	7.90 mm	11.97 mm	7.52 mm	7.34 mm
Cash remaining	20.11 mm	n/a	20.11 mm	16.04 mm	20.49 mm	20.68 mm
Runway (months of cash)	12.9	n/a	12.9	6.8	13.8	14.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

APYX institutional ownership history Ownership history

24.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	32	48	-33.3%
Opened positions	3	6	-50.0%
Closed positions	19	7	+171.4%
Increased positions	5	12	-58.3%
Reduced positions	9	18	-50.0%

13F shares	Current	Prev Q	Change
Total value	10.86 bn	16.25 bn	-33.2%
Total shares	9.27 mm	12.88 mm	-28.0%
Total puts	0.00	1.00 k	EXIT
Total calls	0.00	359.50 k	EXIT
Total put/call ratio	–	0.0	–

Largest owners	Shares	Value	Change
Royce & Associates	2.58 mm	$3.20 bn	+3.4%
Vanguard	1.48 mm	$1.84 bn	0.0%
Horizon Kinetics Asset Management	615.00 k	$762.60 mm	0.0%
Taylor Frigon Capital Management	596.88 k	$740.13 mm	-6.8%
Silverberg Bernstein Capital Management	572.63 k	$710.06 mm	-4.0%
Commonwealth Equity Services	511.56 k	$634.00 k	0.0%
BlackRock	496.82 k	$616.05 mm	NEW
Geode Capital Management	328.21 k	$407.08 mm	+0.5%
Private Advisor	322.32 k	$399.68 mm	+3.9%
Greenwood Capital Associates	257.82 k	$319.70 mm	-4.0%

Largest transactions	Shares	Bought/sold	Change
Archon Capital Management	0.00	-3.12 mm	EXIT
BlackRock	496.82 k	+496.82 k	NEW
BLK BlackRock	0.00	-495.69 k	EXIT
Bridgeway Capital Management	0.00	-140.40 k	EXIT
Caption Management	0.00	-115.55 k	EXIT
STT State Street	0.00	-109.31 k	EXIT
Kingsview Wealth Management	124.45 k	+93.42 k	+301.1%
Royce & Associates	2.58 mm	+85.27 k	+3.4%
Susquehanna International	0.00	-74.80 k	EXIT
Wealth Enhancement Advisory Services	90.80 k	-67.15 k	-42.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

APYX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jan 25	Wendy Lauren Levine	Stock Option (Option to Buy) Common Stock	Grant	Acquire A	No	No	1.42	50,000	71.00 k	50,000
15 Jan 25	Vizirgianakis Stavros G.	Stock Option (Option to Buy) Common Stock	Grant	Acquire A	No	No	1.42	50,000	71.00 k	50,000
15 Jan 25	Shawn David Roman	Stock Option (Option to Buy) Common Stock	Grant	Acquire A	No	No	1.42	100,000	142.00 k	100,000
15 Jan 25	Baylor-Henry Minnie	Stock Option (Option to Buy) Common Stock	Grant	Acquire A	No	No	1.42	50,000	71.00 k	50,000
15 Jan 25	Matthew C Hill	Stock Option (Option to Buy) Common Stock	Grant	Acquire A	No	No	1.42	50,000	71.00 k	50,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Apyx Medical Announces Q4 2024 Revenue Between $14.1M-$14.3M, A 3%-4% Decrease YOY; Advanced Energy Revenue Flat At $12.0M-$12.2M; OEM Revenue Down 17% To $2.1M; FY24 Revenue Between $48.0M-$48.2M, An 8% Decrease YOY; Advanced Energy Down 11% To $38.5M-$38.7M; OEM Up 6% To $9.5M.

13 Jan 25

Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for

Apyx Medical Corp Submits 510(k) Premarket Notification To The U.S. FDA ForTthe AYON Body Contouring System

6 Jan 25

Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it